The Deep Value Graveyard: Five Stocks the Market Left for Dead
Five ASX stocks show the widest price-to-fair-value gaps in the Feb 2026 reporting season. Our analysis asks what the market knows or fears that the models do not, and whether the scepticism is justified.
Every reporting season produces a handful of stocks where the gap between our pipeline's fair value and the market price is so wide that it forces a question: is the model wrong, or is the market? This February, five companies sit at the extreme end of that spectrum, with implied upside ranging from 177% to 770%. They span rare earths, agricultural logistics, SaaS, tourism, and pathology. They share almost nothing in common except that the market has, in each case, priced in a version of the future that is materially worse than our base case.
The analytical challenge with deep value is that the market is often right. Stocks trading at extreme discounts usually carry risks that justify at least some of the gap. The useful exercise is not to dismiss the market's scepticism but to quantify it: what probability of failure is embedded in the current price, and does the actual evidence support that probability? None of these businesses scores above 6.1/10 on our quality framework. These are not high-quality compounders temporarily mispriced. They are businesses with genuine operational challenges, narrow moats, and in several cases unproven management teams. The question is whether the discount is calibrated to the risk, or whether the market is pricing near-certainty of permanent impairment when the evidence supports something closer to a coin flip.
Scorecard
| Company | Sector | Price | Fair Value | Gap | Quality | Bear Case | Market Implied |
|---|---|---|---|---|---|---|---|
| REE (RareX) | Materials | A$0.023 | A$0.20 | +770% | 4.0/10 | A$0.12 (+422%) | <20% production probability |
| LAU (Lindsay Australia) | Industrials | A$0.77 | A$3.55 | +361% | 6.1/10 | A$2.65 (+244%) | Permanent margin compression |
| DUB (Dubber) | IT / SaaS | A$0.014 | A$0.043 | +207% | 4.6/10 | A$0.02 (+43%) | Failed turnaround + customer loss |
| THL (Tourism Holdings) | Consumer Disc. | A$2.28 | A$6.55 | +188% | 4.8/10 | A$1.82 (-20%) | No tourism recovery, NA write-off |
| HLS (Healius) | Health Care | A$0.69 | A$1.91 | +177% | 5.5/10 | A$1.18 (+71%) | Turnaround fails, no MBS relief |
All prices in AUD. Fair values are probability-weighted point estimates from DCF analysis. Quality scores reflect our proprietary business quality framework (1-10 scale).
REE: Pre-Revenue Rare Earth Developer, +770%
RareX is developing Australia's largest undeveloped rare earth deposit at Cummins Range in Western Australia, holding 524 million tonnes of resources at 0.31% total rare earth oxides, sufficient for 20-25 years of production. The company generates zero revenue and will not produce anything until 2030 at the earliest, burning A$3.6 million in FY25 (up from A$2.6 million in FY24) as exploration activity accelerated before the strategic shift toward development mode. At A$0.023 versus our fair value of A$0.20, this is the widest gap in our coverage universe.
The valuation mechanics for a pre-revenue developer are fundamentally different from a producing company. Our A$0.20 fair value uses an asset-based NAV methodology at 64% weighting, which values Cummins Range's discrete project economics at A$0.22 per share, cross-validating the DCF. The probability-weighted framework assigns 55% to the base case (A$0.27 per share, assuming successful development with production beginning 2030 and ramping to 19,000 tonnes of rare earth oxides annually by 2033 at 28% EBITDA margins), 35% to the bear case (A$0.12, reflecting geopolitical premium collapse and distressed fundraising), and 10% to the severe case (A$0.04, representing project abandonment or liquidation). Even the severe case, which effectively assumes near-total failure, sits 74% above the current market price. Each 5 percentage-point shift from severe toward base case probability adds approximately A$0.012 per share to our weighted fair value.
The market's scepticism is straightforward and largely defensible. RareX must fund a A$1.4 billion construction project, financed through an assumed 70% government-backed debt and 30% equity split, with management that has no mine-building track record (credibility 5.5/10). Shareholders face 66-156% cumulative dilution through four to five capital raises before production begins, expanding the share count from 920 million today to between 1,617 million (base case) and 2,478 million (bear case with distressed raises at 30% dilution per raise versus 20% in the base scenario). The company closed FY25 with just A$2.4 million cash plus A$5.0 million in listed investments, providing only 10-11 months of runway at current burn rates, and cash burn accelerates to A$8-9 million annually through the development phase.
The geopolitical premium sustaining rare earth pricing at 30-50% above historical levels is assessed 60% cyclical versus 40% structural, with clear precedent from 2012-15 showing that the premium can collapse within 18 months when Chinese supply discipline breaks. NdPr oxide currently trades at A$155/kg, the 100th percentile of historical pricing, and our model assigns 75% probability to partial mean reversion within two to three years to A$100-125/kg. If Chinese export controls ease or supply discipline breaks, NdPr pricing could revert to A$90/kg, still above the A$70-80/kg historical average but compressing RareX's projected EBITDA margins from 28% to 22% and triggering the bear case funding dynamics. Chinese producers maintain structural 40-60% cost advantages through labour arbitrage and environmental externalisation that Western operators cannot match. At A$0.023, the market assigns less than 20% probability to successful production, which is conservative but not irrational for a sub-A$30 million market cap junior miner.
The counterargument rests on the Mining Lease granted in January 2026, which eliminates the primary failure mode for junior miners. Regulatory rejection accounts for 60-70% of junior mining project failures, and this milestone has not been repriced by the market. The Iluka consortium partnership validates strategic positioning, and RareX sits within an emerging oligopoly where five Western producers will control approximately 80% of non-Chinese supply by 2030. The Q4-2026 metallurgical testing results (validating 80-85% rare earth recovery and 50-70% gallium recovery assumptions) and the Q1-2027 final investment decision are the next de-risking milestones that should compress the uncertainty discount.
LAU: Integrated Agricultural Logistics, +361%
Lindsay Australia bundles temperature-controlled transport, rural merchandise, and retail operations into a single platform serving Australian farming customers through what management calls the "fruit loop" model, where the same truck delivering perishable freight to market returns loaded with rural supplies for the grower. FY25 revenue grew 5.6% to A$850 million, but EBITDA of A$90 million at a 10.6% margin reflected excess capacity in the transport industry suppressing pricing across the sector. The Rural division proved its defensive value, growing profits 10.7% during the same period and demonstrating why the integrated model is more resilient than pure-play competitors.
The gap to our A$3.55 fair value is the most puzzling in this group because the business is profitable, growing, and paying dividends. The FY25 dividend of A$0.038 per share delivers a 4.9% yield at current prices on a conservative 55% payout ratio. The company trades at 7.9x EV/EBITDA (enterprise value divided by earnings before interest, taxes, depreciation, and amortisation) against a peer median of 8.2x on current earnings, but the real opportunity sits in the normalised earnings trajectory. Our forecasts show revenue growing to A$928 million in FY26, A$1,001 million in FY27, and A$1,066 million in FY28, with EBITDA margins recovering from 10.6% to 11.5% in FY26 and 12.0% by FY27. On forward FY26 estimates, the EV/EBITDA multiple drops to 6.6x. EPS is forecast at A$0.098 in FY26 (42% growth off the cyclical trough), rising to A$0.12 in FY27 and A$0.132 in FY28. Each 100 basis points of EBITDA margin recovery above our 12.0% ceiling adds approximately A$0.30 per share to fair value through the operating leverage inherent in a transport fleet with high fixed costs.
ROIC (return on invested capital, measuring how efficiently the business generates profit from its capital base) sits at 6.2%, below the 8.97% cost of capital, which means the business is technically destroying value at the margin today. This is the metric that dominates the market's pricing. But the trajectory matters: our model shows ROIC crossing back above the cost of capital at 8.5% in FY26 and reaching 10.2% by FY27 and 11.0% by FY28. That crossover is the single most important milestone for re-rating because it shifts the analytical assessment from value destruction to value creation. The market appears to be pricing in a scenario between our bear and severe cases, which we assign a combined 30% probability. The bear case of A$2.65 (25% probability) assumes integration delays across all four recent acquisitions, sustained margin compression of 150 basis points, and below-GDP terminal growth, yet it still represents 244% upside from A$0.77. The bull case of A$4.85 (20% probability) assumes successful integration, margin recovery to 12.5%, and cross-selling penetration reaching management's 45% target (from 25% currently), with each 5 percentage points of cross-selling penetration adding approximately A$0.20 per share.
The company completed four acquisitions in 18 months, including SRT Logistics in Tasmania, while maintaining conservative leverage at 1.53x net debt to EBITDA. That leaves ample capacity to continue consolidating a fragmented industry where operator distress is accelerating exits. Management's execution is solid but unproven at this acquisition pace: the single biggest risk is simultaneous integration failure across multiple deals, each requiring management attention, cultural integration, and system harmonisation. If service quality degrades and customer retention falls below 85% from the current 92%, the cross-selling thesis unravels and competitors gain an opening, reducing fair value by approximately A$0.54 per share. The early warning signal is quarterly customer retention data; so long as it stays above 90%, the thesis is intact. The strongest near-term catalyst is transport capacity normalisation over the next 24 months as operator distress accelerates industry exits, with the SRT integration expected to deliver A$1 million or more in synergies by year-end and the new Perth facility opening the Western Australian horticulture corridor.
DUB: Call Recording SaaS Turnaround, +207%
Dubber embeds cloud call recording software into 240 telecommunications carrier networks, earning subscriptions when end customers use the service through their carrier (Cisco, Microsoft Teams, Vodafone). The business model has attractive structural characteristics: 99% recurring revenue, 70% gross margins, and asset-light operations with negative working capital. The company achieved its first profitable month in June 2025 after eight years of losses, with Q2 FY26 delivering A$8.0 million EBITDA at a 19% margin. At A$0.014 versus our fair value of A$0.043, the stock trades at a 67% discount.
Our fair value methodology weights DCF at 65%, trading multiples at 25%, and transaction comparables at 10%. The probability-weighted framework assigns 50% to the base case (A$0.06 per share, assuming sustained execution with revenue recovering from A$42.0 million in FY25 to A$53.9 million by FY27 at 20% EBITDA margins), 35% to the bear case (A$0.02, modelling additional customer losses and dilutive funding), and 15% to the severe case (effective zero, representing a platform trust breach or complete customer exodus). The base case revenue trajectory shows FY26 revenue dipping slightly to A$41.2 million as the VMO2 loss annualises, before recovering to A$53.9 million in FY27 and A$69.0 million in FY28 as Americas scaling and AI feature monetisation take effect. Free cash flow is forecast at A$10.7 million in FY26, A$11.9 million in FY27, and A$12.9 million in FY28. Each A$5 million of incremental annual recurring revenue above our base case adds approximately A$0.005 per share to fair value.
The market's concern is specific and well-founded. The loss of a single customer, Vodafone's VMO2, eliminated 24% of FY24 revenue in one event, and recurring subscriptions declined 5% quarter-on-quarter to A$7.8 million despite growing to 240 carrier partners (management attributed this to "Cisco invoicing changes," though underlying churn likely contributed). Customer concentration creates binary risk: the top ten customers represent an estimated 40-50% of revenue with a Herfindahl-Hirschman index (a measure of concentration where higher numbers mean more reliance on fewer customers) around 2,000. There is no early warning system because customer concentration disclosures are minimal, and losses typically appear suddenly in quarterly reports. A new Tier 1 North American carrier contract provided A$4.6 million upfront, but the ongoing subscription profile remains unclear.
Management credibility scores just 2.1/10 following a A$26.6 million misappropriation scandal, the lowest credibility score in our coverage universe. The competitive moat is narrow, with Microsoft Teams Premium and Zoom adding native recording features that threaten Dubber's value proposition within 12-24 months. Horizontal convergence is the structural risk that distinguishes Dubber from the other companies in this article: the threat is not cyclical recovery failing to materialise but the product category itself being absorbed by larger platforms. AI feature adoption currently sits at 12% of users against a management target of 40%, and the trajectory from 12% to 25% by FY27 needs to generate sufficient revenue per user growth to offset the competitive displacement risk. Americas revenue of A$10.6 million in FY25 targeting A$26.3 million by FY28 provides geographic diversification, but the execution track record in that market is limited.
At A$0.014, the stock prices in a near-certain failed turnaround, which overstates the risk given that breakeven has been achieved, cost discipline has been delivered (operating expenses fell A$5 million through workforce optimisation and facility exits), and cash runway, while limited at A$9.5 million (three to six months if burn resumes), is adequate if profitability holds. The catalyst timeline is measurable: quarterly cash flow sustainability and customer retention become observable within six to nine months, allowing active position monitoring.
THL: Global RV Rental Operator, +188%
Tourism Holdings is the world's largest commercial RV rental operator, owning and manufacturing campervans across Australia, New Zealand, North America, and the UK. The vertically integrated model, building its own fleet rather than purchasing from third parties, gives THL an estimated 20% cost advantage over pure-rental competitors in its core ANZ markets. FY25 revenue reached A$937 million with A$162 million EBITDA, but margins of 17.3% remain below the historical average of 19.4% as North American operations underperform and the 2022 Apollo acquisition integration continues to absorb management attention. EBIT of just A$47 million reflects the gap between EBITDA generation and the heavy depreciation burden of a fleet-intensive business.
The asset backing is the most striking feature of this investment case. Fleet book value implies a liquidation value of A$7.19 per share, more than three times the A$2.28 market price, providing a hard floor that few deep value situations offer. The company trades at 6.1x EV/EBITDA versus a peer median of 8.5x and its own five-year average of 9.8x. On our FY26 EBITDA estimate of A$194 million, with margins recovering to 18.8%, the forward multiple drops further. Our probability-weighted framework assigns 55% to the base case (A$4.43, requiring fleet utilisation improving from 68% toward 75% and tourism arrivals reaching pre-COVID levels by FY27), 20% to the bull case (A$8.85, assuming full tourism recovery plus North American profitability), 20% to the bear case (A$1.82, modelling no tourism recovery and a North American write-off), and 5% to the severe case (A$0.45, representing a leverage-driven restructuring). Each percentage point of fleet utilisation improvement above 68% adds approximately A$0.55 per share to fair value, because fleet costs are largely fixed and incremental rental revenue drops through to EBIT at approximately 60% contribution margin.
The Board rejected a A$2.30 per share takeover approach from BGH Capital, signalling that even a private equity buyer willing to pay a premium could not get the Board to the table at this price. ROIC (return on invested capital) of 6.9% sits materially below the 10.8% cost of capital, meaning the business is currently destroying value, and management's guidance achievement rate of 65-90% reflects a mixed execution track record. The dividend of A$0.065 per share yields roughly 2.9%, but free cash flow is structurally negative due to heavy fleet investment (A$315 million capex in FY25, rising to A$372 million by FY28), so dividends are funded by debt capacity rather than surplus cash. Leverage at 3.1x net debt to EBITDA is the specific risk worth monitoring: a 15% revenue decline would bring the company close to covenant thresholds.
ANZ forward bookings running 25% ahead year-on-year provide early confirmation that the core franchise remains healthy and that the FY26 utilisation improvement thesis has near-term support. The revenue trajectory in our base case shows growth to A$1,031 million in FY26, A$1,118 million in FY27, and A$1,191 million in FY28, with EBITDA margins expanding to 19.5% by FY27 as utilisation improves. North America is the critical swing factor: the division is currently running at a negative EBIT margin, and management is targeting A$15-25 million in annual synergies from the Apollo integration that are not yet proven at scale. If North America continues to consume capital without generating returns, fair value falls by approximately A$2.00 per share. The UK/Ireland strategic review is expected to conclude within 12 months, and a clean exit would release capital and remove a persistent drag on group returns. The A$12 million cost optimisation programme is 85% likely to be achieved based on current run rates.
The bear case of A$1.82 sits only 20% below the current price, while the base case sits 94% above it, creating 4.7:1 upside-to-downside asymmetry from current levels. International tourism at 85% of 2019 levels has clear runway to normalise, and the stock is the purest listed exposure to this recovery in the Asia-Pacific region.
HLS: Pathology Duopolist in Turnaround, +177%
Healius runs Australia's second-largest pathology network with 2,200 collection centres and accredited laboratories, a physical infrastructure that took decades to build and holds roughly 22% of the market in a stable duopoly with Sonic Healthcare. The company sold its Lumus Imaging division in May 2025 for A$965 million, eliminating all debt and simplifying the business to a pure pathology play with a clean balance sheet. First-half FY26 revenue grew 4.4% to A$688 million, and the T27 cost programme delivered A$18 million in annualised savings, ahead of the A$15-20 million target.
The cost trajectory is the core of the turnaround thesis. Labour costs fell from 52% to 49.3% of revenue between Q1 and Q2 FY26, a meaningful shift that validates the T27 efficiency programme. EBIT remains suppressed not by weak trading but by A$222 million in annual depreciation, the legacy of decades of network investment now captured through lease accounting, which overwhelms even a healthy 17.8% EBITDA margin. Our forecasts show group revenue growing from A$1,340 million in FY25 to A$1,393 million in FY26, A$1,449 million in FY27, and A$1,506 million in FY28, with EBITDA holding at A$237-261 million across the forecast period. The EPS trajectory is thin but improving: A$0.016 in FY25, A$0.012 in FY26 (trough), A$0.026 in FY27, and A$0.044 in FY28. EBIT margin recovery from 0.9% in FY26 to 1.9% in FY27 and 3.1% in FY28 is the critical metric because each percentage point of EBIT margin on A$1.4 billion of revenue represents approximately A$14 million of incremental profit, or roughly A$0.21 per share after tax.
At 3.9x EV/EBITDA versus Sonic's 10.5x, the discount to peers is extreme. Sonic operates in the identical Australian pathology market and achieves 10% EBIT margins, confirming that the structural economics support margins Healius has not yet reached. ROIC sits at just 2% against a 9% cost of capital, meaning the business is currently destroying value, and the competitive moat is narrow, lasting an estimated five to seven years before telehealth and Sonic's scale advantage erode it further. The business quality score of 5.5/10 (versus a peer average of 7.0) reflects these constraints. Healius has failed at turnaround programmes before, in 2019-21, and the market carries that institutional memory in the price.
Our probability-weighted framework assigns 55% to the base case (A$2.15 per share), 30% to the bear case (A$1.18), and 15% to the severe case (A$0.47). The upside/downside ratio is 2.3 to 1 from current levels, making this the strongest downside-protected name in the group. Even the bear case fair value of A$1.18 sits 71% above the current A$0.69 price, providing margin of safety that absorbs a significant amount of execution disappointment. The balance sheet, now carrying net cash and A$48.3 million in franking credits, provides a floor that limits permanent capital impairment. Agilex Biolabs, the contract research arm, grew revenue 16% and EBIT 145% in the first half, a quieter but genuine proof point that the simplified business is gaining operational traction beyond the core pathology network.
The genomics division represents the structural growth pocket, expanding at approximately 25% annually, though it remains under 5% of group revenue. Australia's ageing population adds 1-2% annual pathology volume growth regardless of economic conditions, providing a base demand tailwind. No dividend is forecast through at least FY28; the company holds franking credits but cannot deploy them until EBIT recovers meaningfully.
What Would Change Our View
More optimistic on REE: The Q4-2026 metallurgical testing results are the next binary milestone. Recovery rates at or above the 85% TREO level (versus the 80-85% assumption in our base case) would move the project from "plausible" to "confirmed" in terms of process economics and add approximately A$0.03-0.05 per share. A credible financing package announced alongside the Q1-2027 FID, particularly one structured to limit equity dilution below our 66% base case assumption, would compress the dilution discount that accounts for approximately 40% of the gap between our base case of A$0.27 and the current price. NdPr oxide pricing sustaining above A$130/kg through calendar 2026, combined with Chinese export controls tightening rather than easing, would increase our structural probability weighting from 40% to 55-60% and raise fair value by approximately A$0.04 per share.
More optimistic on LAU: Transport capacity normalising ahead of our 24-month timeline, evidenced by industry exit rates accelerating above 3% per quarter and rate recovery visible in LAU's H1 FY26 result, would pull forward the margin recovery and ROIC crossover by six to twelve months. Each quarter of early normalisation adds approximately A$0.15 per share through reduced present value discounting. Cross-selling penetration reaching 35% (from 25%) within 18 months rather than our three-year assumption would validate the platform strategy's customer stickiness and support a higher terminal multiple. Customer retention sustaining above 92% through the integration period would confirm that management can execute multiple acquisitions without degrading the service proposition.
More optimistic on DUB: Sustained quarterly cash flow positivity through Q3-Q4 FY26 would confirm that operational breakeven is durable, not a one-month anomaly. No additional large customer losses through the next four to six quarters would shift the VMO2 loss from "potentially symptomatic" to "confirmed isolated," reducing bear case probability from 35% to 20% and adding approximately A$0.008 per share. AI feature adoption reaching 20-25% by FY27 (from 12% currently) would validate the revenue-per-user growth thesis that underpins the base case, with each 5 percentage points of AI adoption adding approximately A$0.003 per share.
More optimistic on THL: Fleet utilisation reaching 72-73% in the FY26 full-year result (from 68%) would confirm the tourism recovery thesis at the operational level, with each percentage point above 68% adding approximately A$0.55 per share. North American EBIT turning positive in any single quarter would be the first evidence that the Apollo synergies are materialising, reducing bear case probability from 20% to 10% and adding approximately A$0.80 per share to the probability-weighted value. A clean exit from UK/Ireland at book value or above would release capital for debt reduction and remove a drag that suppresses group ROIC by approximately 150 basis points.
More optimistic on HLS: The November 2026 Medicare Benefits Schedule update is the highest-stakes single event across the five companies. A partial fee offset for the Fair Work Commission gender pay ruling adds an estimated A$0.45 per share to fair value and transforms the margin recovery trajectory from "capped" to "open-ended." EBIT margin clearing 3% in the FY26 full-year result would confirm the base case trajectory, with each additional percentage point of EBIT margin representing approximately A$0.21 per share. Labour costs sustaining below 49.5% of revenue for two consecutive quarters would provide evidence that the T27 programme is delivering structural, not temporary, improvement.
Less optimistic on all five: The shared downside risk across this group is that deep value becomes deeper. None of these businesses has a strong enough competitive position or management track record to ensure that the discount closes on the investor's timeline rather than the market's. RareX may never reach production. DUB may lose another large customer. THL's North American operations may continue to bleed indefinitely. HLS may fail at another turnaround programme. LAU may discover that four simultaneous integrations overwhelm management bandwidth. The February 2026 Reserve Bank rate increase to 3.85% and above-target inflation at 3.8% create an adverse macro backdrop for businesses already under operational stress: higher rates compress tourist spending (THL), defer elective medical testing (HLS), extend transport overcapacity (LAU), increase the cost of project financing (REE), and reduce enterprise software budgets (DUB). A prolonged period of above-target inflation would amplify each of these pressures simultaneously.
Bottom Line
The common thread across these five stocks is not sector or strategy but the nature of the discount. In every case, the market has priced in a specific failure scenario, whether that is production never happening, a turnaround collapsing, customers leaving, tourism not recovering, or margins not improving, and has assigned that scenario a probability far higher than our analysis supports. The most telling data point is the bear case column in the scorecard: for four of the five companies, even the downside scenario in our framework sits materially above the current price. Only THL's bear case (A$1.82) falls below its market price, and only by 20%.
RareX at A$0.023 carries the widest gap but also the most binary risk profile, with a pre-revenue business model, 66-156% dilution ahead, and no management track record in mine construction, offset by the Mining Lease de-risking that the market has not repriced and asset-based NAV validation at A$0.22 per share. Lindsay Australia at A$0.77 is the most puzzling discount in the group because it applies to a profitable, dividend-paying business with conservative leverage, where the entire gap traces to a cyclical transport margin trough that our model shows recovering within 24 months. Dubber at A$0.014 presents the narrowest margin of safety, with 2.1/10 management credibility, genuine competitive displacement risk from Microsoft and Zoom, and cash runway of three to six months if profitability does not hold, but the market prices near-certain failure for a business that has demonstrably achieved breakeven. Tourism Holdings at A$2.28 offers the strongest asset backing, with fleet liquidation value of A$7.19 per share providing a tangible floor, the Board's rejection of BGH's A$2.30 bid confirming management's own view of intrinsic value, and 4.7:1 upside-to-downside asymmetry at current levels. Healius at A$0.69 provides the strongest downside protection as a percentage of fair value, with even the bear case 71% above today's price, a clean balance sheet from the Lumus divestiture, and a defined catalyst timeline centred on the November 2026 Medicare schedule update.
The entry points that make the risk-reward compelling differ by company. REE below A$0.05 provides a margin of safety against even the bear case while preserving full exposure to the Mining Lease de-risking re-rating. LAU below A$0.80 (approximately current levels) already prices below the severe case in our framework and offers a margin of safety against our bear case fair value of A$2.65 that absorbs integration failure, margin compression, and below-trend growth simultaneously. DUB below A$0.02 sits inside the bear case fair value range and prices the turnaround as failed, meaning any evidence of sustained profitability reprices the stock materially. THL below A$2.50 preserves the full asymmetry between the A$1.82 bear case and the A$4.43 base case while paying less than 35% of fleet liquidation value. HLS below A$0.75 provides exposure to the November 2026 MBS catalyst at a price where the bear case still delivers 57% upside. In each case, the entry discipline is the same: the risk is real, the quality is low, and the margin of safety must come from price, not from the business itself.
Analysis generated by the Alpha Insights AI research pipeline. All fair values are point estimates subject to model uncertainty. This is not financial advice. Do your own research before making investment decisions.